Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Advanced HCC: Understanding Systemic and Immunotherapies

At a Glance

For advanced HCC, doctors often shift from localized treatments like TACE to systemic therapies that travel through the bloodstream. The current standard of care uses powerful immunotherapy and targeted therapy combinations, such as Atezo/Bev or the STRIDE regimen, to fight cancer and extend life.

Return to Home

When HCC reaches the Advanced stage (BCLC C), it means the cancer has begun to grow into the liver’s major blood vessels or has spread to other parts of the body [1]. At this point, “local” treatments like TACE are often no longer the best choice because they only target one spot [2]. Instead, doctors use systemic therapies—medicines that travel through your entire bloodstream to find and fight cancer cells wherever they are [3].

The Shift from TACE to Systemic Therapy

Many patients begin their journey with TACE (the procedure that plugs the tumor’s blood supply). However, there is a point called TACE refractoriness [4]. This is when the tumors stop responding to TACE or the liver becomes too stressed by the procedure [4][5].

Continuing TACE beyond this point can actually harm your liver function, which might prevent you from being healthy enough to try other life-extending medicines [2][6]. Your doctor will monitor your scans and bloodwork to “catch” this moment and transition you to systemic therapy at the right time [7][8].

First-Line Treatment Options

Today, the standard of care for advanced HCC has shifted away from older drugs toward powerful combinations of immunotherapy and targeted therapy [3].

1. Atezolizumab + Bevacizumab (“Atezo/Bev”)

This is currently a preferred first-line treatment for most patients [9].

  • How it works: Atezolizumab is an immunotherapy that “unmasks” cancer cells so your immune system can find and kill them [3]. Bevacizumab is an anti-angiogenic drug that starves the tumor of its blood supply and helps the immunotherapy work better [3][10].
  • Key benefit: In clinical trials, this duo helped patients live longer than the previous standard-of-care pills [10][11].

2. The STRIDE Regimen (Tremelimumab + Durvalumab)

A newer option, called the STRIDE regimen, uses two different types of immunotherapy together [12].

  • The “Prime and Sustain” approach: It starts with a single, high “priming” dose of Tremelimumab followed by regular doses of Durvalumab [12][13].
  • Key benefit: A major study (the HIMALAYA trial) showed that this combination significantly improved survival compared to older treatments [13][14]. It is often a good choice for patients who cannot take “Atezo/Bev” due to bleeding risks [14].

3. Targeted Pills: Lenvatinib

If immunotherapy isn’t the right fit, Lenvatinib is a daily pill that blocks multiple signals the cancer uses to grow [15]. It is known for its ability to shrink tumors effectively, which can be very important for managing symptoms [15][16].

The Hope of “Conversion Therapy”

While these drugs are often used for life extension, researchers are seeing an exciting trend called conversion therapy [17]. In some cases, systemic therapies work so well that they shrink “unresectable” tumors down to a size where they can be safely removed by a surgeon or even qualify for a transplant [17][18]. If your tumor shows a significant response, your team may re-evaluate your case for a potentially curative surgery [19][20].

Treatment Type How It’s Given Key Strength
Atezo + Bev Immunotherapy + Targeted IV Infusion Often considered the most effective first choice [3].
STRIDE Dual Immunotherapy IV Infusion Proven long-term survival with a unique dosing schedule [13].
Lenvatinib Targeted (TKI) Daily Pill Excellent at shrinking tumors (high response rate) [15].

Your oncology team will choose between these based on your liver’s health (your Child-Pugh score) and your personal health history, such as whether you have high blood pressure or a risk of stomach bleeding [11][21].

Common questions in this guide

What does it mean to be refractory to TACE?
TACE refractoriness happens when liver tumors stop responding to the TACE procedure, or the liver becomes too stressed by it. Continuing TACE at this point can harm your liver function, so doctors typically transition to systemic therapies instead.
What is the Atezo/Bev treatment for advanced liver cancer?
Atezo/Bev is a combination of two drugs: atezolizumab, an immunotherapy that helps your immune system fight cancer, and bevacizumab, a targeted drug that starves the tumor's blood supply. It is a preferred first-line treatment that has been shown to help patients live longer.
How does the STRIDE regimen work for HCC?
The STRIDE regimen combines two different types of immunotherapy drugs, tremelimumab and durvalumab. It starts with a high priming dose of one drug followed by regular doses of the second, and is often a good option for patients who cannot take other treatments due to bleeding risks.
What is conversion therapy in advanced HCC?
Conversion therapy occurs when systemic medicines shrink previously inoperable liver tumors so much that they can safely be removed by a surgeon. If the cancer responds exceptionally well to treatment, your doctor may re-evaluate you for surgery or a liver transplant.
How do doctors choose the right systemic therapy for liver cancer?
Your oncology team will select a treatment based on your liver's health, often measured by a Child-Pugh score, and your personal medical history. Factors like high blood pressure, risk of stomach bleeding, or autoimmune diseases play a major role in choosing between immunotherapy infusions or targeted daily pills.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently 'refractory' to TACE, and is it time to move to a drug that works throughout my whole body?
  2. 2.Which first-line option is better for me: the 'Atezo/Bev' combination or the 'STRIDE' regimen?
  3. 3.Am I at a high risk for bleeding, and how does that affect my ability to take drugs like Bevacizumab?
  4. 4.Is there a chance that these drugs could shrink my tumor enough to make surgery or a transplant possible later (conversion therapy)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.

    Wang YY, Zhong JH, Xu HF, et al.

    Alimentary pharmacology & therapeutics 2019; (49(2)):202-210 doi:10.1111/apt.15074.

    PMID: 30506713
  2. 2

    A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.

    Kudo M, Han KH, Ye SL, et al.

    Liver cancer 2020; (9(3)):245-260 doi:10.1159/000507370.

    PMID: 32647629
  3. 3

    Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.

    Brown ZJ, Gregory S, Hewitt DB, et al.

    Surgical oncology 2022; (42()):101748 doi:10.1016/j.suronc.2022.101748.

    PMID: 35395582
  4. 4

    Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists.

    Zhong BY, Wang WS, Zhang S, et al.

    Journal of clinical and translational hepatology 2021; (9(4)):521-527 doi:10.14218/JCTH.2021.00049.

    PMID: 34447681
  5. 5

    Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition.

    Zhang S, Zhong BY, Zhang L, et al.

    World journal of gastrointestinal surgery 2022; (14(6)):528-537 doi:10.4240/wjgs.v14.i6.528.

    PMID: 35979416
  6. 6

    Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence.

    Zhang S, Wang WS, Zhong BY, Ni CF

    Journal of clinical and translational hepatology 2022; (10(4)):740-747 doi:10.14218/JCTH.2021.00336.

    PMID: 36062280
  7. 7

    Development and Validation of a Radiomics Nomogram Based on Magnetic Resonance Imaging and Clinicoradiological Factors to Predict HCC TACE Refractoriness.

    Dong Y, Hu J, Meng X, et al.

    Cancer management and research 2025; (17()):1441-1455 doi:10.2147/CMAR.S486561.

    PMID: 40692943
  8. 8

    Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.

    Niu XK, He XF

    World journal of gastroenterology 2021; (27(2)):189-207 doi:10.3748/wjg.v27.i2.189.

    PMID: 33510559
  9. 9

    Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

    Yano S, Kawaoka T, Yamasaki S, et al.

    Cancers 2023; (15(22)) doi:10.3390/cancers15225406.

    PMID: 38001666
  10. 10

    Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

    Finn RS, Qin S, Ikeda M, et al.

    The New England journal of medicine 2020; (382(20)):1894-1905 doi:10.1056/NEJMoa1915745.

    PMID: 32402160
  11. 11

    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

    Cheng AL, Qin S, Ikeda M, et al.

    Journal of hepatology 2022; (76(4)):862-873 doi:10.1016/j.jhep.2021.11.030.

    PMID: 34902530
  12. 12

    Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma.

    Song X, Kelley RK, Green M, et al.

    Clinical pharmacology and therapeutics 2023; (114(4)):874-882 doi:10.1002/cpt.2992.

    PMID: 37422678
  13. 13

    Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

    Abou-Alfa GK, Lau G, Kudo M, et al.

    NEJM evidence 2022; (1(8)):EVIDoa2100070 doi:10.1056/EVIDoa2100070.

    PMID: 38319892
  14. 14

    Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.

    Sangro B, Galle PR, Kelley RK, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(23)):2790-2799 doi:10.1200/JCO.23.01462.

    PMID: 38805668
  15. 15

    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

    Kudo M, Finn RS, Qin S, et al.

    Lancet (London, England) 2018; (391(10126)):1163-1173 doi:10.1016/S0140-6736(18)30207-1.

    PMID: 29433850
  16. 16

    Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.

    Zhao Y, Zhang YN, Wang KT, Chen L

    Biochimica et biophysica acta. Reviews on cancer 2020; (1874(1)):188391 doi:10.1016/j.bbcan.2020.188391.

    PMID: 32659252
  17. 17

    Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.

    Zhou H, Song T

    Bioscience trends 2021; (15(3)):155-160 doi:10.5582/bst.2021.01091.

    PMID: 34039818
  18. 18

    Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.

    Zhu XD, Huang C, Shen YH, et al.

    Liver cancer 2021; (10(4)):320-329 doi:10.1159/000514313.

    PMID: 34414120
  19. 19

    Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.

    Cao Y, Tang H, Hu B, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2023; (25(7)):775-787 doi:10.1016/j.hpb.2023.03.004.

    PMID: 36973160
  20. 20

    Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study.

    Han R, Gan L, Sun L, et al.

    Journal of hepatocellular carcinoma 2024; (11()):1835-1844 doi:10.2147/JHC.S482803.

    PMID: 39360035
  21. 21

    Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.

    Cai H, Chen S, Tang S, et al.

    Cancer immunology, immunotherapy : CII 2025; (74(3)):88 doi:10.1007/s00262-025-03942-3.

    PMID: 39891746

This page provides educational information about systemic and immunotherapies for advanced HCC. Always consult your oncologist or hepatologist to determine the safest and most effective treatment plan for your specific liver function and medical history.

Get notified when new evidence is published on Hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.